Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Therapy

Study Background and Research Question

Melanoma, the most aggressive skin cancer, is marked by rapid progression, high metastatic potential, and frequent resistance to immune checkpoint inhibitors (ICIs). One central contributor to both tumor progression and immune evasion is the loss or mutation of the phosphatase and tensin homolog (PTEN) tumor suppressor gene. PTEN is a critical negative regulator of the PI3K/Akt signaling pathway, controlling cell proliferation, apoptosis, and metabolism. Loss of PTEN function is common in melanoma, glioblastoma, breast, and prostate cancers, leading to unchecked tumor growth, diminished immune infiltration, and poor patient outcomes (paper). The question addressed by Kim et al. (2025) is whether localized, non-invasive restoration of PTEN expression via mRNA delivery can overcome immune resistance and suppress tumor growth in melanoma.

Key Innovation from the Reference Study

The central innovation is the development of a hyaluronate-conjugated lipid nanoparticle (HA-LNP) platform for the efficient, topical delivery of PTEN mRNA directly through the skin. Unlike conventional LNPs that use polyethylene glycol (PEG) for stability—an approach associated with potential immunogenicity and hypersensitivity—these HA-LNPs incorporate a novel amphiphilic HA-dimyristoyl glycerol (HA-DMG) conjugate. This modification enables direct integration of hyaluronate into the LNP bilayer during self-assembly, enhancing stability, colloidal uniformity, and, crucially, CD44-mediated targeting of tumor and skin-resident immune cells (paper). HA, a biocompatible glycosaminoglycan, facilitates deep skin penetration and receptor-mediated uptake, making it particularly suited for transdermal delivery in skin cancer applications. By efficiently encapsulating large mRNA payloads, this system enables robust and targeted restoration of PTEN expression in melanoma tissues—effectively reversing tumor-promoting molecular defects and immune evasion mechanisms.

Methods and Experimental Design Insights

The study's experimental workflow involved the synthesis of HA-DMG, formulation of HA-LNPs, encapsulation of PTEN mRNA, and comprehensive evaluation of the resulting nanoparticles in both in vitro and in vivo melanoma models. Key design elements included:

• Self-assembly of HA-LNPs with HA-DMG, replacing PEG-lipids and simplifying the formulation process.
• Encapsulation of in vitro transcribed PTEN mRNA, optimized for stability and translation.
• Analysis of nanoparticle size, charge, and colloidal stability, confirming suitability for transdermal delivery.
• Evaluation of skin penetration and CD44-mediated uptake using CD44-positive melanoma cell lines and mouse models.
• Assessment of PTEN protein restoration, induction of immunogenic cell death (ICD), and changes in tumor immune microenvironment.
• In vivo testing of antitumor efficacy, immune activation, and toxicity following topical application in melanoma-bearing mice.

This rigorous, multi-parameter approach allowed for the systematic validation of each step, from nanoparticle engineering to functional biological outcomes.

Protocol Parameters

• assay: LNP size | value_with_unit: ~100 nm diameter | applicability: ensures efficient skin penetration and tumor accumulation | rationale: nanoparticles in the 100 nm range maximize tissue uptake and minimize rapid clearance | source_type: paper
• assay: mRNA encapsulation efficiency | value_with_unit: >90% | applicability: critical for delivering sufficient PTEN mRNA to tumor cells | rationale: high encapsulation minimizes loss and maximizes therapeutic payload | source_type: paper
• assay: topical application dose | value_with_unit: 10 μg mRNA per application (in vivo) | applicability: effective for tumor suppression without toxicity in mouse models | rationale: sufficient to restore PTEN without eliciting adverse effects | source_type: paper
• assay: PTEN mRNA structure | value_with_unit: Cap 1, poly(A) tail | applicability: boosts translation and stability in cytosolic delivery | rationale: mimics endogenous mRNA, reduces immune activation | source_type: workflow_recommendation
• assay: storage | value_with_unit: -40°C or below | applicability: preserves mRNA integrity pre-encapsulation | rationale: prevents RNase degradation and repeated freeze-thaw cycles | source_type: product_spec

Core Findings and Why They Matter

The HA-LNP platform demonstrated several critical advances:

• Efficient transdermal delivery and tumor targeting: HA-LNPs penetrated deep skin layers and selectively targeted CD44-positive melanoma cells and antigen-presenting cells, confirming the utility of HA-mediated delivery (paper).
• Restoration of PTEN expression: Topical application of PTEN mRNA@HA-LNPs led to robust restoration of PTEN protein in tumor tissue, reversing molecular hallmarks of PTEN loss (e.g., reduced PI3K/Akt signaling).
• Immunogenic cell death and antitumor immunity: The restored PTEN expression induced immunogenic cell death, increased tumor infiltration by T cells, and reversed immune evasion. In combination, these effects led to significant inhibition of tumor growth in vivo.
• Safety and translational potential: Minimal toxicity was observed in treated animals, supporting the clinical relevance of a non-invasive, mRNA-based immunotherapy for localized melanoma (paper).

These findings collectively indicate that the rational engineering of HA-LNPs for PTEN mRNA delivery can overcome critical barriers in cancer immunotherapy, specifically addressing resistance mechanisms and the challenge of effective, localized gene restoration.

Comparison with Existing Internal Articles

Several recent internal articles contextualize and extend the impact of this reference study:

• Transdermal PTEN mRNA-HA-LNPs: Advancing Skin Cancer Immunotherapy summarizes the rationale for HA-mediated mRNA delivery, echoing findings on enhanced tumor penetration and immune activation. The current reference study adds detailed mechanistic and translational validation.
• EZ Cap™ Human PTEN mRNA: Advancing Tumor Suppressor Gene ... discusses the design of mRNA reagents optimized for stability, translation, and immune evasion. The use of Cap 1-structured, polyadenylated mRNA highlighted there is directly relevant to the success of the HA-LNP platform, which requires high-quality mRNA inputs to maximize therapeutic benefit.
• Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Therapy covers similar ground, emphasizing the importance of delivery vector design and the translational promise of mRNA-based local immunotherapy.

Together, these articles form a cohesive narrative around the technical and translational advancements in tumor suppressor gene mRNA delivery, with the reference paper providing pivotal experimental evidence.

Limitations and Transferability

While the HA-LNP platform demonstrates clear advantages over PEG-LNPs and viral vectors, several limitations remain:

• Species and model specificity: Most data are derived from murine models; human skin and tumor microenvironments may differ in penetration, uptake, and immune response (paper).
• Manufacturability and scalability: While the HA-DMG lipid is described as scalable, further validation under GMP and in clinical settings is required.
• Long-term expression and repeat dosing: The transient nature of mRNA expression may necessitate repeated dosing, the safety and immunogenicity profile of which needs further study.
• Target restriction: The approach is best suited for accessible, CD44-positive tumors such as melanoma, with limited immediate applicability to non-cutaneous malignancies.

Transferability to other solid tumors or systemic applications will require additional studies to address tissue-specific barriers and immune microenvironments.

Research Support Resources

For researchers aiming to replicate or extend these workflows, high-quality, Cap 1-structured tumor suppressor gene mRNA is critical. EZ Cap™ Human PTEN mRNA (SKU R1025, APExBIO) provides a robust, in vitro transcribed mRNA with a Cap 1 structure and poly(A) tail, mimicking endogenous mRNAs for improved stability, immune compatibility, and translation. This reagent is suitable for encapsulation in lipid nanoparticles and can be used for both in vitro and in vivo gene therapy research (source: workflow_recommendation). For best results, follow established storage and handling protocols to preserve mRNA integrity.